<DOC>
	<DOCNO>NCT00686686</DOCNO>
	<brief_summary>Subjects psoriasis receive intravenous infliximab 5 mg/kg give 2-hour period Weeks 0 , 2 , 6 ( induction therapy ) evaluate efficacy infliximab Week 18 . Subjects achieve &gt; =75 % improvement Psoriasis Pustulosa Palmoplantaris Area Severity Index ( PPPASI ) score Week 8 AND deterioration PPPASI score 50 % Week 8 Week 12 receive additional infusion Week 12 .</brief_summary>
	<brief_title>Study Evaluate Efficacy Infliximab Induction Therapy Patients With Palmoplantar Psoriasis ( PPP ) ( Study P04555 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>1870 year age time enrollment ; male female . Women childbearing potential men must use adequate birth control measure continue use measure 6 month receive last infusion study agent . Plaquetype psoriasis evidence mild moderate psoriasis elsewhere Psoriasis Pustulosa Palmo Plantaris ( PPPP ) 6 month duration least . Adhere study visit schedule protocol requirement . Capable give informed consent prior study related procedure . Avoid prolong sun exposure , include tan booths ultraviolet ( UV ) light source study . Eligible accord countryspecific tuberculosis ( TB ) screening , eligibility assessment , prevention rule . Chest xray within 3 month prior first infusion evidence malignancy , infection , fibrosis . Screening laboratory test result within parameter specify protocol . Have form psoriasis besides palmoplantaris pustular form . Pregnant , nursing , plan pregnancy within 6 month last infusion . Previous treatment infliximab therapeutic agent target reduce tumornecrosis factor ( TNF ) , include limited etanercept , thalidomide , CDP870 , D2E7 . Other inflammatory disease might confound evaluation benefit infliximab therapy , include limited , rheumatoid arthritis ( RA ) , ankylose spondylitis , systemic lupus erythematosus , Lyme disease . Used investigational drug within previous 1 month 5 time half life investigational agent , whichever long , 3 month biologic unknown half life . Received systemic medications/treatments could affect psoriasis PASI evaluation within 1 month prior study . Used topical medications/treatments could affect psoriasis PASI evaluation within 2 4 week baseline visit . Treated antiCD4 antibody last 6 month . Received systemic immunosuppressive within 4 week prior first infusion . Received within 3 month prior first infusion expect receive live virus bacterial vaccination trial 3 month last infusion . History chronic recurrent infectious disease , include limited chronic renal infection , chronic chest infection , recurrent urinary tract infection , open , drain infect skin wound ulcer . Serious infection hospitalize receive IV antibiotic infection previous 2 month . Have opportunistic infection . Herpes zoster infection within 2 month baseline . Infected human immunodeficiency virus ( HIV ) , hepatitis B C. History clinically significant adverse event ( AEs ) murine chimeric protein human/murine recombinant product . Current sign symptom severe , progressive , uncontrolled renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , cardiac , neurologic , cerebral , psychiatric disease . History demyelinate disease symptom suggestive multiple sclerosis optic neuritis . Systemic lupus erythematosus . Transplanted organ . History lymphoproliferative disease , include lymphoma , sign symptom suggestive possible lymphoproliferative disease , lymphadenopathy unusual size location . Malignancy within previous 5 year . Concomitant diagnosis congestive heart failure ( CHF ) . Unable unwilling undergo multiple venipuncture poor tolerability lack easy access vein . Substance abuse problem within previous 3 year . Hypersensitivity reaction/adverse reaction paracetamol/acetaminophen , antihistamine , topical corticosteroid . Participation another trial use investigational agent procedure trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>